Given lack of strong evidence supporting the benefits of adjvuant RT in resected pancreatic adenocarcinoma (with results of the ongoing RTOG 0848 unavailable possibly until after 2020), what clinicopathologic features of the disease would help you decide wither to offer a combined modality adjuvant therapy or not?